Document Type


Publication Date



Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Cancer Risk and Prevention Program

MeSH Headings

Medical Oncology, Physician-Patient Relations



• Genomic tumor testing (GTT) is a new technology and a cornerstone of the “precision medicine” movement in cancer care.

• GTT uses next-generation genome sequencing technology to identify somatic variants in tumor cells.

• By identifying somatic variants that predict responses to cancer therapies, GTT can help tailor therapy to individual patients, making them more effective.

• However, due to the fact that GTT also detects many variants of uncertain significance, its clinical value is currently unproven.

• When using GTT, physicians counsel patients about both its benefits and its limitations, but the ideal goals and content of these physician-patient discussions have not been clearly defined.


Lambrew Research Retreat

Acknowledgements: The Maine Cancer Genomics Initiative (MCGI) is funded by the Harold Alfond Foundation, and conducted in partnership with the Jackson Laboratory and the MMCRI Center for Outcomes Research and Evaluation (CORE)



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.